Tag #Biopharma

Showing 1 to 3 of 3 results

cnbc.com
🌐 85% Global Worthiness
News related image

Dover Corp. Stock Jumps on Strong 2025 Outlook Despite Q4 Shortfall

Dover Corporation's Q4 2024 revenue reached $1.93 billion, slightly missing estimates, but exceeding EPS expectations at $2.20; its strong 2025 outlook, driven by organic bookings growth and margin expansion across segments, led to a nearly 4% stock increase to around $205 per share.

Progress

48% Bias Score

Decent Work and Economic Growth
smh.com.au
🌐 75% Global Worthiness
News related image

ASX Stock Surge: Sparc, Argent Biopharma Lead Market Gains

Sparc's share price soared to an 11-month high after announcing stage-two of its hydrogen JV, while Argent Biopharma jumped 64 percent following a successful US\$4.5 million capital raise; Australian Mines rose 60 percent on increased scandium resources; and Dimerix climbed 44 percent after a deal w...

Progress

44% Bias Score

Affordable and Clean Energy
cnbc.com
🌐 75% Global Worthiness
News related image

Goldman Sachs Predicts 25% Surge in US M&A Activity in 2025

Goldman Sachs predicts a 25% surge in US M&A transactions in 2025, driven by a business-friendly environment under President Trump's second term, highlighting Insmed, Electronic Arts, and Unity Software as potential merger targets with varying probabilities.

Progress

40% Bias Score

Decent Work and Economic Growth

Showing 1 to 3 of 3 results